Edition:
United Kingdom

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

10.20USD
13 Dec 2017
Change (% chg)

$0.25 (+2.51%)
Prev Close
$9.95
Open
$9.95
Day's High
$10.45
Day's Low
$9.95
Volume
151,254
Avg. Vol
159,934
52-wk High
$13.15
52-wk Low
$4.85

Summary

Name Age Since Current Position

Alan Heller

61 2009 Chairman of the Board

Vipin Garg

58 2013 President, Chief Executive Officer, Director

Richard Eisenstadt

56 2014 Chief Financial Officer

Dorothy Engelking

55 2010 Vice President of Regulatory Affairs

Thomas McDonnell

43 2015 Chief Commercial Officer

Beth Hecht

2015 Director

Paul Edick

62 2015 Non-Executive Director

Bryant Fong

2009 Non-Executive Director

Gregory Robitaille

2009 Non-Executive Director

John Schmid

53 2015 Non-Executive Director

Biographies

Name Description

Alan Heller

Mr. Alan Heller is the Chairman of the board of directors of the company. Mr. Heller has been an Operating Partner at Water Street Healthcare Partners, LLC, since January 2006. Mr. Heller was President and CEO of American Pharmaceutical Partners from October 2004 until May 2005, and prior to that was President of Global Renal Operations at Baxter International from September 2000 until January 2004. Earlier, Mr. Heller served as President of Searle Operations at the time of its integration with Pharmacia Corporation. He currently serves as Chairman of the boards of directors of privately-held Celerity Pharmaceuticals, Inc. and Custopharm, Inc. and as a member of the board of directors of BioClinica, Inc. Mr. Heller holds an M.B.A. from DePaul University and a B.S. from the University of Illinois, Chicago.

Vipin Garg

Dr. Vipin K. Garg, Ph.D., is the Chief Executive Officer, President and Director of the company. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme Inc., now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000, as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994, as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992, and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.

Richard Eisenstadt

Mr. Richard Eisenstadt is the Chief Financial Officer of the company. Prior to joining NEOS, he served as Chief Financial Officer of ArborGen Inc. from June 2013 to May 2014, and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc. now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.

Dorothy Engelking

Ms. Dorothy Engelking is the Vice President of Regulatory Affairs of the company. Prior to joining us, Ms. Engelking served as Vice President of Kendle International, Inc. from July 2008 to July 2009, Senior Vice President of Regulatory Affairs at Xanodyne Pharmaceutics, Inc. from March 2006 to July 2008, and as Vice President of Regulatory Affairs at Watson Pharmaceuticals Inc., now Actavis plc (NYSE: ACT) from January 1999 to March 2006. She received her B.S. in Chemistry and M.S. in Analytical Chemistry from South Dakota School of Mines and Technology, and holds a Regulatory Certificate from the Regulatory Affairs Professional Society.

Thomas McDonnell

Mr. Thomas McDonnell is the Chief Commercial Officer of the company. Prior to joining us, Mr. McDonnell spent ten years with Shire, most recently as Vice President of U.S. Marketing in the Neuroscience Business Unit from December 2013 to March 2015. From August 2012 to November 2013, he was Vice President, General Manager of Adult Psychiatry at Shire. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR. From 1997 to 2005, he held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals. Mr. McDonnell received his B.A. in Marketing from Muhlenberg College.

Beth Hecht

Ms. Beth P. Hecht is Director of Neos Therapeutics, Inc. Ms. Hecht has served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, Inc., since October 2012. Previously, Ms. Hecht served as Senior Vice President and General Counsel of The Sun Products Corporation from March 2009 to October 2012. From February 2008 to January 2009, Ms. Hecht was Senior Advisor for Life Sciences and Consumer Products at Axiom, and from June 2001 to December 2007, Ms. Hecht served as Executive Vice President, General Counsel and Secretary of MedPointe Pharmaceuticals. Ms. Hecht earned a B.A. from Amherst College and a J.D. from Harvard Law School.

Paul Edick

Mr. Paul R. Edick is the Non Executive Director of the company. He is currently the Managing Partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities, a company he founded in 2007. From July 2010 until November 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics, which was merged with Actavis plc in November 2014. Prior to that, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals from 2008 to 2010, Chief Executive Officer of MedPointe Healthcare Inc. from 2006 to 2008, and President of Pharmaceutical Operations at MedPointe from 2002 to 2006. Mr. Edick has served on the boards of directors of NewLink Genetics Inc. and Circassia Ltd. since 2011. Mr. Edick holds a B.A. in Psychology from Hamilton College in Clinton, NY.

Bryant Fong

Mr. Bryant Fong is the Non Executive Director of the Company. Since October 2013, he has served as founding General Partner at Biomark Capital, LLP a life sciences venture capital fund. Prior to Biomark Capital, Mr. Fong was a Managing Director at Burrill & Company, from 1998 to 2013. Mr. Fong received his B.A. in Biochemistry from the University of California at Berkeley. Mr. Fong currently serves on the boards of several life science companies including ADMA Biologics, where he serves on the audit and compensation committee, JHL Biotech, Biozeus and i2Dx.

Gregory Robitaille

Mr. Greg Robitaille is the Non Executive Director of the company. Since July 2011, Mr. Robitaille has managed Corporate Development activities at Water Street Healthcare Partners. From April 2009 to July 2011, Mr. Robitaille served as Executive Vice President for Corporate Development for Sarnova LLC, a portfolio company of Water Street Healthcare Partners. Mr. Robitaille holds a B.A. from Hamilton College and an M.B.A. from Columbia University.

John Schmid

Mr. John Schmid is the Non Executive Director of the company. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc., a publicly traded biotechnology company, from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to that, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. He currently serves as chairman of the board of directors of Speak, Inc. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.

Basic Compensation